DNAC SEC filings, in plain English
Everything Social Capital Suvretta Holdings Corp. III has filed with the SEC that we hold — 40 filings, newest first, 3 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: Exhibit 99.1 to an 8-K of ProKidney Corp. (Nasdaq: PROK): the August 10, 2026 press release reporting Q2 2026 results. Why it matters: Cash fell $43.3 million in the quarter and the stated runway to mid-2027 ends before the Q2 2027 topline is fully behind the company. The confirmatory endpoint readout is not expected until the second half of 2029.
What changed: The 10-Q filed under Commission file number 001-40560 is that of ProKidney Corp. (Nasdaq: PROK) for the quarter ended June 30, 2026, with 208,926,941 Class A and 93,395,714 Class B shares outstanding as of August 10, 2026. Cash and equivalents fell to $74,868 thousand from $108,537 thousand and marketable securities to $106,696 thousand from $161,480 thousand, taking total assets to $249,016 thousand from $335,574 thousand. Why it matters: Cash and marketable securities of $181.6 million against operating expenses of $48.5 million a quarter is under four quarters of runway at the current rate, and R&D spending rose 39% year over year. The Class B exchange transfers economic interest from the non-controlling holders into the public company, which is why Class A share count rose 47% in six months while total assets fell.
What changed vs 2026-05-15going concern APPEAREDgoing-concern doubt1 moved
- Going-concern doubt
- not statedstated
SpacBrain reads this as the substantial-doubt sentence is in this filing and not in the previous one.
The clause …“or that profitability, if achieved, can be sustained. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The Company believes that, based on its current business plan, its existing cash”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: ProKidney Corp., the successor to Social Capital Suvretta Holdings Corp. III (DNAC), called its 2026 annual meeting for Thursday, May 28, 2026 at 10:00 a.m. Eastern Time, held both at 399 Boylston Street, Suite 350, Boston and virtually by live webcast, with proxy materials distributed on or about April 17, 2026. Beneficial ownership is calculated on 141,987,953 shares of Class A common stock and 159,978,404 shares of Class B common stock issued and outstanding as of April 8, 2026. Board biographies include Mr. Legorreta, founder and CEO of Royalty Pharma plc. Why it matters: Class B shares outnumber Class A - 160.0 million against 142.0 million - so the founder and pre-deal holders retain outright voting control of the company the DNAC trust financed, and public Class A holders cannot carry any proposal on their own. With no trust or redemption right remaining, the value of the Class A stock depends entirely on clinical outcomes decided by a board the Class A block does not elect.
sponsor loans outstandingnothing moved · 1 with no prior record of ours
- Sponsor loans outstanding
- $35.0Mnot matched in this filing
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
sponsor loans outstandingnothing moved · 1 with no prior record of ours
- Sponsor loans outstanding
- $35.0Mnot matched in this filing
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.